Abstract
The effects of endomorphin-1 (EM1) on behavioral responses and on the hypothalamic-pituitary-adrenal system were investigated in mice. Locomotor activity was measured in an “open-field” apparatus, with parallel recording of the numbers of rearings and groomings. Different doses of the peptide (250 ng to 5 µg) were administered to the animals intracerebroventricularly 30 min before the tests. EM1 caused significant increases in the locomotor activity and the number of rearings. The effect of EM1 on the basal corticosterone secretion was also investigated. At a dose of 5 µg, the peptide significantly increased plasma corticosterone level. The corticotropin-releasing hormone (CRH) antagonist α-helical CRH9–41, applied 30 min prior to EM1 administration, completely abolished the increases in both locomotion and the number of rearings and attenuated the corticosterone release evoked by EM1. These results suggest that the EM1-induced increases in locomotion and rearing activity as well as the pituitary-adrenal activation are mediated by CRH.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Goldberg, I. E., Rossi, G. C., Letchworth, S. R., Mathis, J. P., Ryan-Moro, J., Leventhal, L., Su, W., Emmel, D., Bolan, E. A., and Pasternak, G. W. (1998). J. Pharmacol. Exp. Ther. 286, 1007–1013.
Zadina, J. E., Hackler, L., Ge, L. J., and Kastin, A. J. (1997). Nature 386, 499–502.
Martin-Schild, S., Gerall, A. A., Kastin, A. J., and Zadina J. E. (1999). J. Comp. Neurol. 405, 450–471.
Akil, H., Watson, S. J., Young, E., Lewis, M. E., Khachaturian, H., and Walker, J. M. (1984). Ann. Rev. Neurosci. 7, 223–255.
Stone, L. S., Fairbanks, C. A., Laughlin, T. M., Nguyen, H. O., Bushy, T. M., Wessendorf, M. W., and Wilcox, G. L. (1997). Neuroreport 8, 3131–3135.
Przewlocka, B., Mika, J., Labuz, D., Toth, G., and Przewlocki, R. (1999). Eur. J. Pharmacol. 19, 189–196.
Jalowiec, J. E., Panksepp, J., Zolovick, A. J., Najam, N., and Herman, B. H. (1981). Pharmacol. Biochem. Behav. 15, 477–484.
Motta, V. and Brandao, M. L. (1993). Pharmacol. Biochem. Behav. 44, 119–125.
Asakawa, A., Inui, A., Momose, K., Ueno, N., Fujino, M. A., and Kasuga, M. (1998). Neuroreport 13, 2265–2267.
Champion, H. C., Zadina, J. E., Kastin, A. J., Hackler, L., Ge, L. J., and Kadowitz, P. J. (1997). Peptides 18, 1393–1397.
Feuerstein, G. and Faden, A. I. (1982). Life Sci. 31, 2197–2200.
Zadina, J. E., Martin-Schild, S., Gerall, A. A., Kastin, A. J., Hackler, L., Ge, L. J., and Zhang, X. (1999). Ann. NY Acad. Sci. 897, 136–144.
Sim, L. J., Liu, Q., Childers, S. R., and Selley, D. E. (1998). J. Neurochem. 70, 1567–1576.
Monory, K., Bourin, M. C., Spetea, M., Tömböly, C. Tóth, G., Matthes, H. W., Kieffer, B. L., Hanoune, J., and Borsodi, A. (2000). Eur. J. Neurosci. 12, 577–584.
Zadina, J. E., Harrison, L. M., Ge, L. J., Kastin, A. J., and Chang, S. L., (1994). J. Pharmacol. Exp. Ther. 270, 1086–1096.
Sanchez-Blazquez, P., DeAntoio, I., Rodriguez-Diaz, M., and Garzon, J. (1999). Antisense Nucleic Acid Drug Dev. 9, 253–260.
Burford, N. T., Tolbert, L. M., and Sadee, W. (1998). Eur. J. Pharmacol. 19, 123–126.
Kuschinsky, K. and Hornykiewicz, O. (1974). Eur. J. Pharmacol. 26, 41–50.
Gibson, A., Ginsburg, M., Hall, M., and Hart, S. L. (1979). Br. J. Pharmacol. 65, 139–146.
Meites, J., Bruni, J. F., Van Vugt, D. A., and Smith, A. F. (1979). Life Sci. 24, 1325–1336.
Mönnikes, H., Heymann-Mönnikes, I., and Tache, Y. (1992). Brain Res. 574, 70–76.
Babbini, M. and Davis, W. M. (1972). Br. J. Pharmacol. 46, 213–224.
Ukai, M., Toyoshi, T., and Kameyama, T. (1989). Neuropharmacology 28, 1033–1039.
Mickley, G. A., Mulvihill, M. A., and Postler, M. A. (1990). Psychopharmacology-Berl. 101, 332–337.
Ukai, M. and Kameyama, T. (1985). Brain Res. 337, 352–356.
Katz, R. J. (1979). Int. J. Neurosci. 9, 213–215.
Isaacson, R. L., Danks, A. M., Brakkee, J., Schefman, K., and Gispen, W. H. (1988). Behav. Neural. Biol. 50, 37–45.
Pei, Q., Zetterstrom, T., Leslie, R. A., and Grahame-Smith, D. G. (1993). Eur. J. Pharmacol. 230, 63–68.
Jezova, D., Vigas, M., and Jurcovicova, J. (1982). Life Sci. 31, 307–314.
Morio, H., Tatsuno, I., Hirai, A., Tamura, Y., and Saito, Y. (1996) Brain Res. 741, 82–88.
Telegdy, G. (1987). Neuropeptides and brain function. Karger: Basel, Switzerland.
Pliska, V. (1994). Trends Pharmacol. 15, 178–181.
Becker, C., Hamon, M., Cesselin, F., and Benoliel, J. J. (1999). Synapse 34, 47–54.
Veldhuis, H. D. and de Wied, D. (1984). Pharmacol. Biochem. Behav. 21, 707–713.
Tazi, A., Swerdlow N. R., LeMoal, M., Rivier, J., Vale, W., and Koob, G. F. (1987). Life Sci. 41, 41–49.
Tömböly, Cs., Spetea, M., Borsodi, A., and Tóth, G. (1999). Czech. J. Phys. 49/S1, 893–896.
Zenker, N. and Bernstein, D. E. (1958). J. Biol. Chem. 231, 695–701.
Purves, H. D. and Sirett, N. E. (1965). Endocrinology 77, 366–374.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bujdosó, E., Jászberényi, M., Tömböly, C. et al. Effects of endomorphin-1 on open-field behavior and on the hypothalamic-pituitary-adrenal system. Endocr 14, 221–224 (2001). https://doi.org/10.1385/ENDO:14:2:221
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1385/ENDO:14:2:221